Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/16/16 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
42 |
| 11/16/15 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
55 |
| 08/14/15 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
52 |
| 05/20/15 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
46 |
| 05/15/15 | NT 10-Q | Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB |
|
4 | |
| 11/14/14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
54 |
| 08/14/14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
44 |
| 05/15/14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
48 |
| 11/15/13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
51 |
| 11/15/13 | NT 10-Q | Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB |
|
3 |
